CLNA — Celon Pharma SA Share Price

0.000.00%
pl flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m+5.03%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w Highn/a
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total RevenuePLNm128.78107.12125.24102.25139.27205.27239.511.91%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-7.89-48.86+14.95-61.01+83.4n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Celon Pharma SA EPS forecast chart

Profile Summary

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
October 25th, 2012
Public Since
April 13th, 2009
No. of Employees
514
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
pl flag iconWarsaw Stock Exchange
Shares in Issue
96,000,000
Blurred out image of a map
Address
ul. Ogrodowa 2A, Kielpin, 05-092
Web
https://celonpharma.com/
Phone
+48 227515933
Contact
Malgorzata Siewierska
Auditors
PricewaterhouseCoopers Polska sp. z o.o. Audyt sp.k.

CLNA Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email